Sothema: Revenue Increases by 19% While Net Debt Decreases by 9%

Moroccan Pharmaceutical Laboratory Achieves Consolidated Revenue of 2.736 Billion Dirhams by September 2026
The Moroccan pharmaceutical laboratory reported a consolidated revenue of 2.736 billion dirhams by the end of September 2026. Its investments reached 130 million dirhams, an increase of 165%, while its net debt was reduced to 758 million dirhams, down from 833 million at the end of 2025.
Sothema continues its growth trajectory by enhancing its industrial capacities and diversifying its product portfolio while improving its financial balance. As of the end of September 2026, the Moroccan pharmaceutical group has invested 130 million dirhams, a significant increase from 49 million during the same period last year, marking a 165% rise.
This growth is accompanied by a sustained increase in commercial activity and a decrease in consolidated net debt, which has declined by 9% compared to the end of December 2025.
Commercial Growth Driven by Core Activities
In the third quarter of 2026, Sothema achieved a consolidated revenue of 940 million dirhams, compared to 757 million during the same period in 2025, representing a 24% increase.
Over the first nine months of the year, the group’s revenues reached 2.736 billion dirhams, a 19% rise. This growth is primarily driven by the solid performance of core activities, particularly in the treatment of chronic diseases.
Cardiology, diabetology, and ophthalmology continue to support the laboratory’s sales. Simultaneously, new growth drivers are gradually gaining importance, notably oncology through Axess Pharma and dialysis solutions developed by Soludia. However, the group does not disclose the specific contributions of these activities to its overall revenue.
Investments Increase by 165%
To support the development of its activities, Sothema has substantially increased its investment efforts. The 130 million dirhams invested since the beginning of the year have primarily been allocated to the enhancement of industrial capacities and the acquisition of rights for the Cialis brand and associated products in Morocco.
In the third quarter alone, investments amounted to 18 million dirhams, down from 21 million the previous year, indicating a 14% decline. Thus, the growth seen over the first nine months largely concentrated in the first half of the year.
Despite this financial effort, the group has managed to reduce its consolidated net debt. As of September 30, 2026, net debt stood at 758 million dirhams, compared to 833 million at the end of December 2025, a reduction of 75 million dirhams.
Sothema attributes this improvement to the management of its financial resources and the optimization of its financing structure.
New Products to Expand the Portfolio
In addition to its industrial investments, the laboratory continues to enhance its product offerings. Since January 2026, six new products have been launched in the Moroccan market, including three in the third quarter.
These products include two dietary supplements aimed at pediatrics and one product tailored to the needs of dialysis and oncology patients.
The regulatory activity also underpins this strategy. As of the end of September, Sothema had obtained 28 marketing authorizations and registration certificates in Morocco, while 18 additional applications had been submitted. In the third quarter alone, the group secured nine new authorizations and submitted seven applications.
Africa and the Middle East as Growth Drivers
Internationally, Sothema is pursuing its commercial expansion efforts, with a particular focus on French-speaking Africa and the Middle East.
Since the beginning of the year, the laboratory has obtained 31 authorizations and registration certificates in foreign markets, including 13 in the third quarter. Concurrently, 23 applications have been submitted internationally, of which 11 were during the last three months.
These regulatory advancements represent a preliminary step toward the commercialization of new products and align with the group’s desire to progressively strengthen its presence beyond the Moroccan market.
Sothema Focuses on Diversification to Strengthen Growth
As the 2026 fiscal year comes to a close, the group showcases a combination of commercial growth, accelerated investments, and reduced net debt.
The continuation of this trajectory will depend notably on the strengthening of specialized activities, the contributions of new products, and the realization of international development projects.
As Sothema celebrates its 50th anniversary in 2026, its objectives now extend beyond mere sales growth. The laboratory aims to consolidate its industrial base, diversify its revenue sources, and maintain its financial stability to support medium- and long-term development.




